Tourmaline Bio, Inc. (TRML)
NASDAQ: TRML · Real-Time Price · USD
47.87
+0.02 (0.04%)
At close: Oct 10, 2025, 4:00 PM EDT
47.88
+0.01 (0.02%)
After-hours: Oct 10, 2025, 7:50 PM EDT
Tourmaline Bio Employees
Tourmaline Bio had 74 employees as of December 31, 2024. The number of employees increased by 30 or 68.18% compared to the previous year.
Employees
74
Change (1Y)
30
Growth (1Y)
68.18%
Revenue / Employee
n/a
Profits / Employee
-$1,195,595
Market Cap
1.24B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 74 | 30 | 68.18% |
| Dec 31, 2023 | 44 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
TRML News
- 6 days ago - Tourmaline Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Tourmaline Bio, Inc. - TRML - Business Wire
- 13 days ago - Novartis announces commencement of tender offer to acquire Tourmaline Bio - GlobeNewsWire
- 4 weeks ago - TOURMALINE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Tourmaline Bio, Inc. - TRML - Business Wire
- 4 weeks ago - This Small Biotech Stock Is Surging Today. Here's Why. - Investopedia
- 4 weeks ago - Tourmaline Bio surges after Novartis $1.4 billion acquisition; analysts see strong fit - Invezz
- 4 weeks ago - This Biopharma Stock Is Soaring 58%. Novartis Is Acquiring It. - Barrons
- 4 weeks ago - Novartis to buy U.S. biotech in latest deal targeting firms in $1 billion to $3 billion range - Market Watch
- 4 weeks ago - Novartis Agrees to Buy Tourmaline Bio in $1.4 Billion-Dollar Deal - WSJ